Antihemophilic Factor Human Recombinant

證據等級: L5

預測適應症: 8 個

Antihemophilic Factor (Human Recombinant): From Hemophilia A to Primary Release Disorder of Platelets

One-Sentence Summary

Antihemophilic Factor (Human Recombinant) is a recombinant blood coagulation Factor VIII (rFVIII), classically used to control and prevent bleeding episodes in patients with Hemophilia A (congenital FVIII deficiency). The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, with a prediction score of 99.96%; however only 2 publications currently support this direction and no clinical trials have been registered for this specific indication.

Quick Overview

Item	Content
Original Indication	Hemophilia A — congenital Factor VIII deficiency (not registered in Saudi Arabia)
Predicted New Indication	Primary Release Disorder of Platelets
TxGNN Prediction Score	99.96%
Evidence Level	L4 (genetic/mechanistic studies only)
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known clinical information, Antihemophilic Factor (Human Recombinant) is a recombinant form of human coagulation Factor VIII; its efficacy in controlling bleeding in Hemophilia A has been well-established over decades, and mechanistically it may provide compensatory support in primary platelet release disorders.

Recombinant FVIII functions as a critical cofactor in the intrinsic tenase complex (FVIIIa + FIXa), dramatically amplifying thrombin generation. Thrombin itself is a potent platelet activator via PAR-1 and PAR-4 receptors. In primary platelet release disorders — characterized by impaired dense granule or alpha-granule secretion — this downstream thrombin amplification pathway could theoretically compensate for inadequate primary hemostasis by maximizing activation of the platelets that are present.

However, this remains a compensatory downstream mechanism rather than targeted therapy. The two supporting publications (a large-scale GWAS linking FVIII/VWF levels to platelet aggregation, and a three-generational pedigree study showing compound FVIII/PTGS-1 variants amplify hemorrhage severity) provide biological plausibility for a FVIII–platelet interaction but constitute indirect genetic evidence only. This mechanistic link is exploratory and does not yet constitute clinical evidence of therapeutic benefit.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38320121	2024	Genetic Association Study (GWAS)	Blood	Whole-genome sequencing of up to 45,289 TOPMed participants identifies genetic loci associated with circulating FVIII and VWF levels; confirms FVIII and VWF are critical to both coagulation and platelet aggregation, providing indirect genetic context for an FVIII–platelet release link
27629384	2016	Mechanistic/Genetic Study	J Thromb Haemost	Three-generational pedigree study demonstrating that co-existent damaging variants in FVIII and prostaglandin synthase-1 (PTGS-1/COX-1) amplify hemorrhage severity; PTGS-1 variant causes functional defects in the arachidonic acid platelet pathway, showing FVIII level interacts with platelet secretion-related pathways

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN high score (99.96%) reflects graph-level proximity among hemophilia-spectrum bleeding disorders rather than direct therapeutic evidence. Available support consists of two genetic studies (L4), no registered clinical trials, and no Saudi Arabia regulatory standing — insufficient to advance this repurposing hypothesis.

To proceed, the following is needed:

Preclinical proof-of-concept: At least one in vitro or animal study specifically testing whether rFVIII-mediated thrombin amplification improves hemostasis in a platelet release disorder model
MOA documentation: Retrieve complete FVIII mechanism of action and pharmacodynamic profile from DrugBank to enable formal mechanistic analysis
Safety dossier: Obtain package insert warnings and contraindications (currently a Blocking data gap per DG001) before any clinical feasibility assessment
Case series search: Conduct a targeted literature search for cases where rFVIII was used off-label in patients with combined FVIII deficiency and platelet secretion defects, which may provide real-world mechanistic clues
Comparator assessment: Evaluate whether established rescue therapies for platelet release disorders (e.g., desmopressin, platelet transfusion) leave an unmet need that rFVIII could address

Note on a higher-priority candidate: Among all eight predicted indications, Acquired Coagulation Factor Deficiency (rank 4, evidence level L2) carries substantially stronger evidence — 5 clinical trials (including Phase 2/3 completed studies of recombinant porcine FVIII in acquired hemophilia A) and 20 publications, with guideline support from UKHCDO/ISTH for human rFVIII use in low-titer inhibitor patients. This indication warrants a separate Proceed with Guardrails evaluation report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.